FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899227260> ?p ?o ?g. }

• W2899227260 endingPage "2847" @default.
• W2899227260 startingPage "2837" @default.
• W2899227260 abstract "Abstract Denosumab (DNM) is a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL) that has been licensed for the treatment of different types of osteoporosis. However, the prospective data for the evaluation of DNM efficacy on transfusion-dependent thalassemia (TDT)–induced osteoporosis are rather limited. Thus, we conducted a randomized, placebo-controlled, double-blind, phase 2b clinical trial to evaluate DNM in TDT osteoporosis. Patients were assigned to receive either 60 mg DNM (n = 32) or placebo (n = 31) subcutaneously on day 0 and 180 during a total of 12 months of follow-up. The percentage increase of L1-L4 bone mineral density was higher in the DNM group than the placebo group (5.92% ± 5.25% vs 2.92% ± 5.56%, respectively; P = .043), whereas the advantage of DNM regarding wrist bone mineral density was much higher compared with placebo (−0.26% ± 5.31% vs −3.92% ± 8.71%, respectively; P = .035). No grade 3 or 4 toxicity was observed. DNM reduced pain scores that remained unaltered in the placebo group. DNM showed a significant reduction of soluble RANKL (sRANKL), sRANKL/osteoprotegerin ratio, C-telopeptide of collagen type I, tartrate-resistant acid phosphatase isoform-5b, and bone-specific alkaline phosphatase between baseline and the 12th month (P &lt; .01 for all comparisons) without changes in dickkopf-1, sclerostin, and osteocalcin. On the contrary, placebo patients showed an increase in sRANKL, osteoprotegerin, dickkopf-1, sclerostin, C-telopeptide of collagen type I, tartrate-resistant acid phosphatase isoform-5b, and bone-specific alkaline phosphatase during the study period (P &lt; .01 for all comparisons). In conclusion, DNM increased lumbar spine and wrist bone mineral density and reduced pain and bone remodeling markers, and thus it is another valuable option for the management of TDT-induced osteoporosis. This trial was registered at www.clinicaltrials.gov as #NCT02559648." @default.
• W2899227260 created "2018-11-09" @default.
• W2899227260 creator A5008317279 @default.
• W2899227260 creator A5018110033 @default.
• W2899227260 creator A5020431685 @default.
• W2899227260 creator A5021725324 @default.
• W2899227260 creator A5041407463 @default.
• W2899227260 creator A5050531750 @default.
• W2899227260 creator A5080629810 @default.
• W2899227260 creator A5082276282 @default.
• W2899227260 creator A5091608170 @default.
• W2899227260 date "2018-10-31" @default.
• W2899227260 modified "2023-10-04" @default.
• W2899227260 title "Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial" @default.
• W2899227260 cites W1030819271 @default.
• W2899227260 cites W129097224 @default.
• W2899227260 cites W1521321020 @default.
• W2899227260 cites W1522603015 @default.
• W2899227260 cites W1523620087 @default.
• W2899227260 cites W1969247685 @default.
• W2899227260 cites W1979720361 @default.
• W2899227260 cites W1979896888 @default.
• W2899227260 cites W1986309799 @default.
• W2899227260 cites W1997986666 @default.
• W2899227260 cites W1998462722 @default.
• W2899227260 cites W2003117351 @default.
• W2899227260 cites W2014588446 @default.
• W2899227260 cites W2019591478 @default.
• W2899227260 cites W2023293653 @default.
• W2899227260 cites W2023303423 @default.
• W2899227260 cites W2029963804 @default.
• W2899227260 cites W2044212277 @default.
• W2899227260 cites W2046530009 @default.
• W2899227260 cites W2063030629 @default.
• W2899227260 cites W2083201027 @default.
• W2899227260 cites W2083656328 @default.
• W2899227260 cites W2084092260 @default.
• W2899227260 cites W2084518320 @default.
• W2899227260 cites W2094716322 @default.
• W2899227260 cites W2100415227 @default.
• W2899227260 cites W2102587806 @default.
• W2899227260 cites W2110063014 @default.
• W2899227260 cites W2113697838 @default.
• W2899227260 cites W2119498754 @default.
• W2899227260 cites W2139860898 @default.
• W2899227260 cites W2144196227 @default.
• W2899227260 cites W2149775776 @default.
• W2899227260 cites W2154771217 @default.
• W2899227260 cites W2160005424 @default.
• W2899227260 cites W2165011173 @default.
• W2899227260 cites W2193440419 @default.
• W2899227260 cites W2339716350 @default.
• W2899227260 cites W2414767221 @default.
• W2899227260 cites W2515968746 @default.
• W2899227260 cites W2762553308 @default.
• W2899227260 cites W2772146267 @default.
• W2899227260 cites W4243887616 @default.
• W2899227260 cites W4252350389 @default.
• W2899227260 doi "https://doi.org/10.1182/bloodadvances.2018023085" @default.
• W2899227260 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6234378" @default.
• W2899227260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30381400" @default.
• W2899227260 hasPublicationYear "2018" @default.
• W2899227260 type Work @default.
• W2899227260 sameAs 2899227260 @default.
• W2899227260 citedByCount "15" @default.
• W2899227260 countsByYear W28992272602019 @default.
• W2899227260 countsByYear W28992272602020 @default.
• W2899227260 countsByYear W28992272602021 @default.
• W2899227260 countsByYear W28992272602022 @default.
• W2899227260 countsByYear W28992272602023 @default.
• W2899227260 crossrefType "journal-article" @default.
• W2899227260 hasAuthorship W2899227260A5008317279 @default.
• W2899227260 hasAuthorship W2899227260A5018110033 @default.
• W2899227260 hasAuthorship W2899227260A5020431685 @default.
• W2899227260 hasAuthorship W2899227260A5021725324 @default.
• W2899227260 hasAuthorship W2899227260A5041407463 @default.
• W2899227260 hasAuthorship W2899227260A5050531750 @default.
• W2899227260 hasAuthorship W2899227260A5080629810 @default.
• W2899227260 hasAuthorship W2899227260A5082276282 @default.
• W2899227260 hasAuthorship W2899227260A5091608170 @default.
• W2899227260 hasBestOaLocation W28992272601 @default.
• W2899227260 hasConcept C104317684 @default.
• W2899227260 hasConcept C125870589 @default.
• W2899227260 hasConcept C126322002 @default.
• W2899227260 hasConcept C131075544 @default.
• W2899227260 hasConcept C134018914 @default.
• W2899227260 hasConcept C137620995 @default.
• W2899227260 hasConcept C142724271 @default.
• W2899227260 hasConcept C160160445 @default.
• W2899227260 hasConcept C170033053 @default.
• W2899227260 hasConcept C170493617 @default.
• W2899227260 hasConcept C181199279 @default.
• W2899227260 hasConcept C185592680 @default.
• W2899227260 hasConcept C204787440 @default.
• W2899227260 hasConcept C27081682 @default.
• W2899227260 hasConcept C2776541429 @default.
• W2899227260 hasConcept C2776886416 @default.
• W2899227260 hasConcept C2779277721 @default.

• next